Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.

An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.

Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.

Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.

Provided herein are methods of inhibiting mesangial cell activation in a subject in need thereof.

The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Provided herein are methods of treating kidney diseases in a subject in need thereof.